EBV VCA, IgG Positive or High: What It Means and Why Over 90% of Adults Test Positive

Sample type: Blood

Other names: EBV VCA IgG, EBV VCA IgG Ab, EBV VCA Antibody IgG, EBV Capsid IgG, EBV Capsid Antibody IgG, Epstein Barr VCA IgG, Epstein-Barr VCA IgG, Epstein Barr Virus VCA IgG, EBV Viral Capsid IgG, EBV Viral Capsid Antigen IgG, VCA IgG, VCA IgG Antibody, EBV VCA IgG U/mL, EBV VCA IgG Positive, EBV VCA IgG Blood

Optimal result: 0 – 100 U/mL

Written October 8, 2026

Updated October 8, 2026

By Healthmatters Editorial Team

Peer-reviewed sources

A result above the stored range means your VCA IgG figure sits above the 0 - 100 U/mL this record holds.

The first thing to know is that a high value on its own cannot establish that something is happening now. The CDC states it directly: "High or elevated antibody levels may be present for years and are not diagnostic of recent infection." This antibody appears during the acute phase of infection and then, in CDC's words, "persists for the rest of a person's life" — so a raised value can be the stable, permanent record of an infection from childhood.

The second is that it is not an unusual result. CDC: "Since over 90% of adults have been infected with EBV, most adults will show antibodies to EBV from infection years earlier." One manufacturer's own validation found 93.4% of blood donors positive against its cutoff. A mark above the stored range here can therefore reflect the ordinary state of having met the virus rather than a deviation from it.

What a high value can do is contribute to a pattern, which is a different claim from being interpretable alone. CDC's criteria include it: "Other results that strongly suggest a primary infection are a high or rising level of anti-VCA IgG and no antibody to EBNA after at least 4 weeks of illness." So a high figure read with the other antibodies, in someone who has been ill for a month or more, points somewhere the single number does not. That distinction — isolated figure against pattern — is the whole of how to read this field.

On the height of the number itself, check your own laboratory's documentation. Some VCA IgG assays report a figure but interpret it only qualitatively — one widely used test states that the numeric value above its cutoff does not indicate the amount of antibody present. Others are calibrated quantitatively, with a documented linear range. Which you have determines whether the distance above the cutoff carries information at all.

And read the mark against the cutoff printed on your own report rather than the range stored here. LOINC classifies this measurement as an arbitrary concentration: there is no international standard behind U/mL for this test, so a figure and a threshold only mean something together, on the same report. What your laboratory called the result — negative, equivocal or positive against its own cutoff — is the part that is always interpretable, and a value can fall inside the interval stored here while your laboratory still classifies it as positive.

What a high result does not tell you. How recently you were infected: the antibody persists for life, so its presence carries no date. Whether the virus is active: antibody level is not an activity measure. Whether EBV explains your symptoms: with over 90% of adults carrying the virus, finding the antibody in someone with symptoms establishes no causation. And whether you are protected — this antibody documents exposure, not protective immunity, because EBV persists latently rather than being cleared. There is no symptom list to read off a high figure.

It is not a cancer finding. The EBV-based screening programme for nasopharyngeal carcinoma uses IgA antibodies and plasma EBV DNA, in middle-aged adults in high-risk endemic regions, and is explicitly not recommended in low-risk regions — a VCA IgG on a general panel is a different antibody class against a different target combination, and has not been validated as a cancer screen.

Reaching for a different number does not settle the activity question either. EBV DNA by PCR measures viral DNA and has established uses in the workup of EBV-associated lymphoproliferative disease, in assessing risk after transplant and in monitoring immunosuppressed patients. But a positive result at a low copy number "may not distinguish between clinically insignificant, latently infected cells and primary infection."

The useful step is to take the whole EBV panel to whoever ordered it, with the timeline of any symptoms, rather than to act on this line. CDC notes that interpreting these tests "requires familiarity with these tests and access to the patient's clinical information."

Read what your laboratory called the result, not where the number sits inside the stored interval. On this test the meaningful distinction is the one the laboratory makes — negative, equivocal or positive against its own cutoff — and a value can fall within the stored 0 - 100 U/mL interval while your laboratory still classifies it as positive. The number and the classification are different things, and the classification is the one that means something.

Where the laboratory has classified the result as negative, that generally means no serologic evidence of EBV infection. CDC describes the pattern plainly: susceptibility to EBV is indicated when "people lack antibodies to the VCA antigen." Given that over 90% of adults have been infected, being in this group is unusual for an adult and entirely ordinary for a child.

Two readings are worth distinguishing, and this line cannot separate them by itself. One is that you have genuinely not encountered the virus — which means a first infection remains possible, and a first EBV infection in adolescence or adulthood is more likely to cause a symptomatic illness than one in early childhood. The other is an infection too early to have produced a detectable antibody response yet. CDC notes that "in rare cases, people with active EBV infections may not have detectable EBV-specific antibodies," so a negative result in someone who is currently unwell does not close the question. The IgM antibody, the rest of the panel and the clinical timeline are what resolve it.

So a negative result does not by itself settle whether you have been exposed, if the test was taken during an illness. If it was taken while you were well — before a transplant, for instance, or to establish susceptibility — it is a more straightforward answer, and it belongs with the clinician who asked the question.

Read any mark against the cutoff printed on your own report. The units here are arbitrary — there is no international standard behind U/mL for this test — so a value that is negative on one laboratory's scale cannot be compared with another's threshold. Assays also differ in what their figure is for: some interpret it only qualitatively, others are calibrated quantitatively, and your laboratory's documentation settles which you have.

A negative result is not a problem to fix and nothing on it needs treating.

This measures IgG antibodies to the Epstein-Barr virus capsid antigen in blood. Your report carries a figure in U/mL and your laboratory's classification of it — negative, equivocal or positive — and the classification is the part that is always interpretable. The unit is an arbitrary concentration per LOINC, so it is not comparable between methods, and assays differ: some interpret their figure only qualitatively, others are calibrated quantitatively.

A positive result indicates EBV infection, past or current. CDC puts the adult figure at over 90% infected, and states anti-VCA IgG "appears in the acute phase of EBV infection, peaks at 2 to 4 weeks after onset, declines slightly then persists for the rest of a person's life".

It is not a measure of protective immunity: EBV persists latently rather than being cleared, so the antibody documents exposure.

On a high figure: "High or elevated antibody levels may be present for years and are not diagnostic of recent infection." A high value alone cannot establish recent infection or reactivation, though CDC includes a high or rising level with absent EBNA, after four weeks of illness, among patterns suggesting primary infection.

An equivocal result does not establish whether infection is present; repeat testing and the panel resolve it. Read it all with the clinician who ordered it.

At a Glance

This measures IgG antibodies to the viral capsid antigen of Epstein-Barr virus — the shell of the virus — in blood. It tells you whether this virus has been met, now or previously.

For most people the answer is yes. CDC: "Since over 90% of adults have been infected with EBV, most adults will show antibodies to EBV from infection years earlier." A positive result here is the common finding.

The unit matters too. This is reported in U/mL, and those units are arbitrary — LOINC classifies the measurement as an arbitrary concentration, so no international standard sits behind the number. The cutoff printed on your own report is the only one that applies to it.

What a positive result actually tells you

That you have been infected with EBV — currently or in the past. Laboratory documentation for this test puts it exactly that way, so it is not a past-infection marker alone, and that matters if you are unwell now.

The timing is why. CDC: "Anti-VCA IgG appears in the acute phase of EBV infection, peaks at 2 to 4 weeks after onset, declines slightly then persists for the rest of a person's life." The antibody is already present during an acute infection — 2 to 4 weeks is when it peaks, not when it arrives — and then it never leaves.

Most primary infections happen in childhood and many are silent, which is why people who never knowingly had mononucleosis are surprised to test positive.

Why a lifelong antibody is not a measure of protection

This is the point most often stated backwards, and the correction is narrow.

A positive VCA IgG does not mean your body cleared the virus. EBV is not eliminated. It establishes latency, persisting inside memory B cells, where, as the literature puts it, "the virus remains largely silent for the lifetime of the host."

What follows is a statement about this test, not about immunity in general. VCA IgG documents exposure; it does not measure protective immunity and does not certify protection against EBV-related illness. Protection and persistent infection can coexist: a randomized EBV vaccine trial found roughly 78% efficacy against infectious mononucleosis while having no effect on whether people became infected. So lifelong infection does not make protection impossible — this number is simply not what would show it, either way.

A positive result records that you have encountered the virus, as most adults have. It does not tell you how well it is being handled.

Reading a high number

This is what a quarter of the searches reaching this page ask, and the best answer is a direct quotation.

CDC, on EBV antibody levels: "High or elevated antibody levels may be present for years and are not diagnostic of recent infection."

What that establishes is narrow: a high value on its own cannot establish recent infection or reactivation. It is not a dial showing how active the virus is, and a high figure can sit unchanged for years.

What it does not say is that a high value never contributes. Read with the rest of the panel it can. CDC's own primary-infection criteria include it: "Other results that strongly suggest a primary infection are a high or rising level of anti-VCA IgG and no antibody to EBNA after at least 4 weeks of illness." So high VCA IgG with absent EBNA, in someone ill for a month or more, points somewhere the single number does not.

That is the distinction to take from here: an isolated figure cannot date an infection; the pattern it sits in can contribute. CDC: "the interpretation of EBV antibody tests requires familiarity with these tests and access to the patient's clinical information."

One caution about the figure, and it depends on the assay. Some VCA IgG tests give a qualitative interpretation despite reporting a number — one widely used assay states that the value above its cutoff does not indicate the amount of antibody present. Others are calibrated quantitatively with a documented linear range. Whether the height of your number means anything is a question for your laboratory's documentation.

How to read your result

Read the word, not the number. Your report carries a figure in U/mL and, beside it, your laboratory's classification of it: negative, equivocal or positive against its own cutoff.

Two reasons the classification is the safer thing to read. The units are not comparable between laboratories: LOINC classifies the measurement as an arbitrary concentration, so a threshold from one method does not apply to another's number. And assays differ in what the figure is for — some interpret it only qualitatively, others are calibrated quantitatively with a documented linear range. Your laboratory's documentation settles which you have.

So the question to start from is not how big your number is, but which category your laboratory put it in — and if that is positive, that over 90% of adults share it.

If you remember only one thing

This virus has been met, as it has by over 90% of adults, and the antibody stays for life. A high value on its own cannot establish recent infection or reactivation — CDC: elevated levels "may be present for years and are not diagnostic of recent infection" — though alongside the other antibodies it can contribute to a pattern.

Two people, same result

Two people both get a VCA IgG their laboratory calls positive.

The first had the test on a general panel, feels well, and has no reason to think anything is wrong. For her it is consistent with the ordinary record of an EBV infection she may not remember — the classification she shares with most adults.

The second has been unwell for months, and was tested because a clinician is working through causes. For him the same result is one line in an investigation, read with the rest of the panel and the timeline of his illness. It may well be incidental, since over 90% of adults have been infected and carry this antibody.

The figure and the flag are identical. What differs is the question around it.

What this result cannot tell you

Whether the virus is active right now, from this line alone. CDC states elevated levels may be present for years without indicating recent infection. Read with the other antibodies the panel can speak to current infection; this number alone cannot.

Whether you currently have mononucleosis. Acute infection is identified by a pattern across several antibodies with the clinical picture.

How recently you were infected. The antibody persists for life, so it carries no date.

Whether your symptoms are caused by EBV. With over 90% of adults carrying the virus, finding the antibody in someone with symptoms establishes no causation.

Whether you are protected from EBV-related illness. It documents exposure, not protective immunity.

Whether you have cancer, or will develop it. This antibody has not been validated as a cancer screen — the EBV screening programmes that exist use a different antibody class and viral DNA, in high-risk populations. Set out below.

The cancer question, answered specifically

Some cancers are associated with EBV, and the clearest way to show a routine result is not a cancer signal is to see what a real EBV screen uses.

Screening for nasopharyngeal carcinoma with EBV markers is real and recommended — in defined settings. The 2023 recommendations in the Journal of the National Cancer Institute name "Combined EBV antibody testing for anti-EBV VCA/EBNA1 IgA" and "Plasma EBV DNA by PCR", for middle-aged adults in high-risk endemic regions or adults with a family history in intermediate-risk regions — and explicitly: "Screening is not recommended in NPC low-risk regions."

That screen uses IgA, a different antibody class from the IgG measured here, against a different target combination, in a defined age group, in regions where the disease is common. A VCA IgG on a general panel is none of those, has not been validated as a cancer screen, and a high value on it is not a cancer finding.

Multiple sclerosis comes up for the same reason. EBV infection is strongly associated with later MS and appears to precede it; the large cohort study behind that compared people who had been infected with people who had not. Group-level work has separately reported somewhat higher VCA IgG levels in people with MS than in controls, while finding no relationship between how those levels changed over two years and relapses, progression or treatment response. What none of it provides is a way to turn a routine VCA IgG number into one person's risk. Over 90% of adults have been infected, so a positive result does not distinguish you from most of the population.

Common interpretation mistakes

Reading "positive" as a measure of protection. The antibody documents exposure; it does not measure protective immunity.

Reading a high value on its own as "active" or "recent". CDC states elevated levels may be present for years and are not diagnostic of recent infection — the panel read together is a different matter.

Comparing the number to a cutoff from elsewhere. The units are arbitrary, so a figure and a threshold only mean something together, on one report.

Assuming the size of the number carries meaning without checking whether your assay quantifies. Some interpret their figure only qualitatively.

Reading this line on its own. EBV serology is interpreted as a pattern, alongside clinical information.

Assuming a positive result explains how you feel. With most adults carrying the virus, presence alone establishes nothing about causation.

Questions your doctor may ask

Why was this test ordered, and what question was it meant to answer? Have you ever had diagnosed mononucleosis, and when? What symptoms prompted the test, and how long have they been present? Were the other EBV antibodies run at the same time, and what did they show? Is there an earlier result to compare on the same laboratory's scale? Anything affecting your immune system — a medication, a condition, a transplant? And what would change in your care depending on the answer?

Read together with

A single EBV antibody is not how this is read. The pattern across the panel carries the meaning.

VCA IgM is the short-lived antibody of acute infection, and its presence beside this one is the main thing separating a recent infection from an old one.

EBNA IgG arrives late. CDC: "The presence of antibodies to both VCA and EBNA suggests past infection (from several months to years earlier)." That combination is the clearest signature of an old infection.

Early antigen (EA) IgG appears in the acute phase and is interpreted with the rest.

EBV DNA by PCR measures viral DNA rather than antibody. Its uses are in selected settings — EBV-associated lymphoproliferative disease, risk after transplant, monitoring immunosuppressed patients — not as a general answer to "is my EBV active". And a low-copy positive "may not distinguish between clinically insignificant, latently infected cells and primary infection."

Clinical pearls

An antibody that persists for life cannot date an infection.

Arbitrary units are central here. U/mL here is not standardized, so a figure and its cutoff are a pair, and neither crosses to another assay.

A positive classification where over 90% of adults are positive says little about the individual alone.

Swapping antibody for viral DNA does not settle the activity question: a low-copy positive PCR may not distinguish latently infected cells from primary infection, and PCR's established uses are transplant and immunosuppression.

Clinical Takeaway

This is IgG to the Epstein-Barr virus capsid antigen, measured in blood and reported as a laboratory classification — negative, equivocal or positive — alongside a figure in arbitrary U/mL. A positive result indicates EBV infection past or current — the antibody appears in the acute phase and then, in CDC's words, "persists for the rest of a person's life" — and over 90% of adults have been infected, so a positive finding is the common one. It is not a measure of protective immunity: EBV persists latently rather than being cleared, and this number is not what would show how well it is held. On a high value: "High or elevated antibody levels may be present for years and are not diagnostic of recent infection" — so the figure alone cannot establish recent infection or reactivation, though CDC includes a high or rising level with absent EBNA, after four weeks of illness, among patterns suggesting primary infection. It is not a cancer or MS screening test. Read it with the rest of the panel, against your own report's cutoff, and with whoever ordered it.

In one sentence

Evidence of Epstein-Barr virus infection, past or current, as in over 90% of adults — read against your own laboratory's cutoff and never on its own.

Bottom line

If this line is flagged and you feel well, it is consistent with the ordinary record of an old infection, which over 90% of adults carry. If you were tested because something is wrong, the number belongs inside that investigation rather than at the end of it.

Organize and understand all your lab results

Start organizing — $15/mo →

For Health Professionals Healthmatters Pro Multiple clients’ results in one dashboard. See Pro plans →

EBV VCA, IgG

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →

Frequently Asked Questions

What does a positive EBV VCA IgG mean?

It means you have been infected with Epstein-Barr virus — currently or in the past. Laboratory documentation for this test describes the presence of VCA IgG as indicating past or current EBV exposure, so it is not a past-infection marker alone. For most people the result is unremarkable, because the CDC states that "over 90% of adults have been infected with EBV, most adults will show antibodies to EBV from infection years earlier." The timing explains the range: anti-VCA IgG "appears in the acute phase of EBV infection, peaks at 2 to 4 weeks after onset, declines slightly then persists for the rest of a person's life" — it is present during an acute infection, and 2 to 4 weeks is when it peaks rather than when it first appears. Many primary EBV infections happen in childhood and are mild or silent, so a positive result does not mean you had a diagnosed case of mononucleosis.

Does a positive result mean I am immune to EBV?

Not in the way the question usually means. A positive VCA IgG does not mean your body cleared the virus: EBV is not eliminated after infection — it establishes latency and persists inside memory B cells, where the virus "remains largely silent for the lifetime of the host." What follows is a statement about this test rather than about immunity in general. This antibody documents exposure; it does not measure protective immunity and does not certify protection against EBV-related illness. Protection and lifelong infection can coexist — a randomized EBV vaccine trial reported about 78% efficacy against infectious mononucleosis while having no effect on whether people became infected at all. So persistence does not make protection impossible; it means this number is not what would demonstrate it, in either direction.

My EBV VCA IgG is high. Should I be worried?

The governing sentence comes from the CDC: "High or elevated antibody levels may be present for years and are not diagnostic of recent infection." So a high value on its own cannot establish recent infection or reactivation, and a high figure can sit unchanged for years. Read with the rest of the panel it is a different matter — CDC's criteria include "a high or rising level of anti-VCA IgG and no antibody to EBNA after at least 4 weeks of illness" among results that strongly suggest primary infection. The distinction to hold on to is between an isolated figure and a pattern. Two further things. With over 90% of adults infected, a flag here can mark the ordinary state of having met the virus. And whether the height of the number means anything depends on your assay: some VCA IgG tests state that the numeric value above their cutoff does not indicate the amount of antibody present, while others are calibrated quantitatively.

Does a high EBV VCA IgG mean I have cancer?

No. Some cancers are genuinely associated with EBV, and the clearest way to see that your result is not a cancer signal is to look at what a real EBV cancer screen uses. Screening for nasopharyngeal carcinoma with EBV markers exists and is recommended in defined settings: the 2023 recommendations in the Journal of the National Cancer Institute name "Combined EBV antibody testing for anti-EBV VCA/EBNA1 IgA" and "Plasma EBV DNA by PCR", for middle-aged adults in high-risk endemic regions or those with a family history in intermediate-risk regions — and state that "Screening is not recommended in NPC low-risk regions." Your result is a different antibody class (IgG, not IgA), against a different target combination, and those recommendations state that screening is not recommended in low-risk regions at all. A VCA IgG on a general blood panel has not been validated as a cancer screen, and a high value on it is not a cancer finding. The more basic point holds too: CDC states elevated EBV antibody levels "may be present for years and are not diagnostic of recent infection", so a high number does not establish that anything is happening now.

Can this test tell me if my EBV is reactivating?

Not from this line on its own. CDC states that elevated antibody levels "may be present for years and are not diagnostic of recent infection", and an antibody that persists for life is not a dial showing current viral activity. The obvious next move — measure viral DNA instead — is less decisive than it sounds. EBV DNA by PCR has established uses in the workup of EBV-associated lymphoproliferative disease, in assessing risk after transplant and in monitoring immunosuppressed patients, but a positive result at a low copy number "may not distinguish between clinically insignificant, latently infected cells and primary infection." So it is not a general answer to "is my EBV active" either. If the question behind your search is whether EBV explains how you have been feeling, that belongs with a clinician who can see the whole panel, your history and your timeline — and worth knowing first is that with over 90% of adults carrying this virus, finding the antibody in someone with symptoms does not establish that the virus is causing them.

Why does my result say positive when the page says most adults are positive?

Because on this test positive is the common result, and the word is a classification rather than a verdict. CDC: "Since over 90% of adults have been infected with EBV, most adults will show antibodies to EBV from infection years earlier." Being in the positive group places you with the large majority, and on its own it says little about you specifically. It is worth knowing what the classification is and is not. Your laboratory compares your figure with its own cutoff and reports negative, equivocal or positive, and that comparison is the part you can always rely on. Whether the distance above the cutoff adds anything depends on the assay: some VCA IgG tests state that the numeric value above their cutoff does not indicate the amount of antibody present, while others are calibrated quantitatively. LOINC classifies the unit as an arbitrary concentration either way, so another laboratory's threshold does not apply to your number.

What does a negative EBV VCA IgG mean?

First, read what your laboratory called it rather than the size of the figure — the classification against its own cutoff is the result. Where the laboratory called it negative, that usually means no serologic evidence of EBV infection; CDC describes susceptibility as the situation where "people lack antibodies to the VCA antigen." For an adult this is the less common result, since over 90% have been infected; for a child it is ordinary. Two readings cannot be separated by this line alone. One is that you genuinely have not met the virus, so a first infection remains possible — and a first EBV infection in adolescence or adulthood is more likely to produce a symptomatic illness. The other is an infection too early to have produced a detectable response: CDC notes that "in rare cases, people with active EBV infections may not have detectable EBV-specific antibodies." The IgM antibody, the rest of the panel and the clinical timeline resolve that. Whatever the figure, the units are arbitrary and no threshold from elsewhere applies to it.

What should I look at alongside this result?

The rest of the EBV antibody panel, because this test is interpreted as part of a pattern rather than line by line. VCA IgM is the short-lived antibody of acute infection, and whether it is present beside this one is the main thing separating a recent infection from an old one. EBNA IgG arrives late, and the combination is the clearest signature of an old infection available — CDC: "The presence of antibodies to both VCA and EBNA suggests past infection (from several months to years earlier)." Early antigen (EA) IgG appears in the acute phase and is read with the others. And EBV DNA by PCR measures viral load rather than antibody, which is the test to use where the amount of virus present is what matters. CDC notes that interpreting these tests together "requires familiarity with these tests and access to the patient's clinical information."

Is there a link between EBV and multiple sclerosis?

There is a real and strongly supported association, and the useful detail is what the evidence does and does not give you. A large cohort study of US military personnel found that of 801 people who developed MS, all but one had been infected with EBV beforehand, with a substantially raised risk following infection — a comparison between people who had been infected and people who had not. Separately, group-level studies have reported somewhat higher VCA IgG levels in people with MS than in controls, while finding no relationship between how those levels changed over two years and relapses, progression or treatment response. What none of it supplies is a way to turn a routine VCA IgG number into one person's risk. Since the CDC puts over 90% of adults in the infected group, a positive result does not distinguish you from most of the population, and MS remains uncommon while EBV infection is close to universal. Nothing about your number here is a forecast.

Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

Laboratory Testing for Epstein-Barr Virus (EBV)

Centers for Disease Control and Prevention. Page last reviewed 10 April 2024; accessed 6 October 2026 · 2024 View source ↗
LOINC 5157-3 — Epstein Barr virus capsid IgG Ab [Units/volume] in Serum by Immunoassay

Regenstrief Institute · 2026 View source ↗
Lam WK, King AD, Miller JA, et al. Recommendations for Epstein-Barr virus-based screening for nasopharyngeal cancer in high- and intermediate-risk regions. JNCI. 2023;115(4):355-364

Journal of the National Cancer Institute. doi:10.1093/jnci/djad012 · 2023 View source ↗
Hatton OL, Harris-Arnold A, Schaffert S, Krams SM, Martinez OM. The interplay between Epstein-Barr virus and B lymphocytes: implications for infection, immunity, and disease. Immunol Res. 2014;58(2):268-276

Immunologic Research. doi:10.1007/s12026-014-8496-1. PMID 24619311 · 2014 View source ↗
Barnes K. Infection with Epstein Barr virus increases risk of multiple sclerosis. Commun Med. 2022;2:13

Communications Medicine. doi:10.1038/s43856-022-00076-w · 2022 View source ↗
Epstein-Barr Virus (EBV) Antibodies to Viral Capsid Antigen (VCA), IgG — test 096230

Labcorp · 2026 View source ↗
Sokal EM, Hoppenbrouwers K, Vandermeulen C, et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial. J Infect Dis. 2007;196(12):1749-1753

Journal of Infectious Diseases. doi:10.1086/523813 · 2007 View source ↗
Epstein-Barr Virus — testing guidance

ARUP Consult, ARUP Laboratories. Last update April 2025; accessed 7 October 2026 · 2025 View source ↗
Dominguez-Mozo MI, Lopez-Lozano L, Perez-Perez S, et al. Epstein-Barr Virus and multiple sclerosis in a Spanish cohort: a two-years longitudinal study. Front Immunol. 2022;13:991662

Frontiers in Immunology. doi:10.3389/fimmu.2022.991662 · 2022 View source ↗
Anti-EBV-CA ELISA (IgG) — test instruction

EUROIMMUN Medizinische Labordiagnostika AG · 2026 View source ↗

Article Review Log

Last reviewed October 8, 2026

Originally published October 8, 2026

Reviewed by HealthMatters Editorial Team

Written by Healthmatters Editorial Team

Organize and understand all your lab results

Start organizing — $15/mo →

For Health Professionals Healthmatters Pro Multiple clients’ results in one dashboard. See Pro plans →

Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →

Secure checkout via Stripe · GDPR & HIPAA

We accept results from any lab

LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members

★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel

Member since 2022

★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben

Member since 2021 · tracks across countries

★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra

Functional medicine · 6 yrs on Pro

EBV VCA, IgG Positive or High: What It Means and Why Over 90% of Adults Test Positive

At a Glance

What a positive result actually tells you

Why a lifelong antibody is not a measure of protection

Reading a high number

How to read your result

If you remember only one thing

Two people, same result

What this result cannot tell you

The cancer question, answered specifically

Common interpretation mistakes

Questions your doctor may ask

Read together with

Clinical pearls

Clinical Takeaway

In one sentence

Bottom line

Organize and understand all your lab results

Every lab result you’ve ever had, charted and explained.

Frequently Asked Questions

Related Biomarkers

Related Health Conditions

Pay $250. Track your health forever

What members are saying